SecBot SecBot
DEFA14A ·Filed Apr 27, 2026

SPRO

Spero Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-182256
Proxy solicitation materials
Actionable Insight • Neutral

Monitor post-meeting filings for any share issuance or equity award grants under the new plan. The share authorization increase could precede a future capital raise.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.67
T+0 close · Apr 27, 2026 · via day close
Latest settled
−56.55%
T+60 · $1.16
Vs SPY
−60.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $2.67entry
  2. T+1 · 7mo ago −4.87%α −4.86% · $2.54
  3. T+5 · 7mo ago −6.37%α −8.06% · $2.50
  4. T+20 · 6mo ago +7.12%α +1.65% · $2.86
  5. T+60 · 4mo ago −56.55%α −60.54% · $1.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spero Therapeutics filed additional proxy materials for its 2026 Annual Meeting, scheduled for June 23, 2026. Proposals include electing two Class III directors, ratifying the auditor, advisory vote on executive compensation, doubling authorized shares from 120M to 240M, and adopting a new stock incentive plan. The board recommends a 'For' vote on all items.

Key Financial Metrics

Vote
director election
Meeting
2026-06-23

Key Facts

  • Annual meeting set for June 23, 2026
  • Proposal to increase authorized common shares from 120,000,000 to 240,000,000
  • Proposal to adopt the 2026 Spero Therapeutics, Inc. Stock Incentive Plan
  • All five proposals are recommended 'For' by the board
  • Market cap ~$159M with mixed analyst consensus

Financial Impact

Potential dilution from doubling authorized shares, but no immediate issuance announced.

dilution

Risk Factors

  • Future dilution from authorized share increase
  • Potential overhang if new equity issuance is announced

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-182256
Document: 0001193125-26-182256-index-headers.html0001193125-26-182256
Document: 0001193125-26-182256-index.html0001193125-26-182256
Document: 0001193125-26-182256.txt0001193125-26-182256

Track record

17 reports on SPRO

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
  2. Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  3. Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
  5. Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
  6. Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  7. Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  8. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
  9. Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
  10. Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 8h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026